Viralgen and the Gene2Cure Foundation have announced a manufacturing collaboration for investigational gene therapies for rare and ultra-rare genetic disorders in children. The agreement will initially cover three programs, targeting PUS3 syndrome, Smith-Lemli-Opitz syndrome and GAND.
Under the agreement, Viralgen will provide adeno-associated virus (AAV) manufacturing services using its Aava platform, with the scope of work determined by each program’s requirements and stage of development. Depending on the program, the company will produce material for toxicology studies, clinical use or both. The platform is designed to support manufacturing across different AAV serotypes as programs move from preclinical research into clinical development and, if they advance, into commercial production.
Gene2Cure is a U.S.-based nonprofit that works internationally to develop experimental gene therapies for children with genetic conditions that have few or no treatment options. The foundation is funded by philanthropic donations and brings together researchers, clinicians and manufacturing specialists to move programs from research toward clinical use.
Viralgen is a contract development and manufacturing organization specializing in AAV-based gene therapies, with services ranging from early development through commercial manufacturing. It was founded in 2017 as a subsidiary of AskBio, which is part of the Bayer group.
Viralgen’s facility in San Sebastián, Spain, has three manufacturing suites, each with a capacity of 2,000 liters and certified by Spain’s medicines agency. The site also provides plasmid production, process optimization, fill-finish and in-house quality control testing.